McKesson MCK North American Pharmaceutical — Total other segment expense, net

Other segment segments

Similar metrics at other companies

UAANorth America — Other segment expenses

$384.29M-23.3%

PZZANorth America Commissaries — Other segment expenses

$0—

PZZANorth America Franchising — Other segment expenses

$0—

CBOENorth American Equities — Other segment operating expenses

$33.3M-12.8%

LKQNorth America Segment — Other segment items

-$1M+75.0%

WHRMDA North America — Other segment expenses/(income)

$203M-10.2%

FAQ

What is McKesson's north american pharmaceutical — total other segment expense, net?

McKesson (MCK) reported north american pharmaceutical — total other segment expense, net of $85.87B in Q2 2026.

How has McKesson's north american pharmaceutical — total other segment expense, net changed year-over-year?

McKesson's north american pharmaceutical — total other segment expense, net increased by 4.5% year-over-year, from $82.14B to $85.87B.

What is the long-term trend for McKesson's north american pharmaceutical — total other segment expense, net?

Over 2 years (2024 to 2026), McKesson's north american pharmaceutical — total other segment expense, net has grown at a 13.4% compound annual growth rate (CAGR), from $259.03B to $332.99B.

What does north american pharmaceutical — total other segment expense, net mean?

This metric captures the net total of various operational expenses not directly attributable to the cost of goods sold or primary operating expenses within the North American Pharmaceutical segment. It encompasses overhead, administrative costs, and other miscellaneous segment-level expenditures. Monitoring this helps evaluate the efficiency of the segment's cost structure beyond direct distribution costs.